A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) is a phase 2/3 interventional study registered as NCT06109272, led by AbbVie, and active but no longer recruiting on the registry. Official title: A Phase 2/3, Randomised Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab in Subjects With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment. Planned enrolment is 660 participants (estimated). The study started in 2024-01-11 and primary completion is expected in 2030-09. No results have been posted on ClinicalTrials.gov.